| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Magnesium stearate does not have a defined pharmacological target as it is a pharmaceutical excipient rather than a therapeutic agent. The compound is used as a lubricant, anti-adherent, and glidant in tablet and capsule formulations. It reduces friction between particles and between the tablet formulation and the compression equipment during manufacturing. Its function is to improve the manufacturing process rather than to interact with biological targets.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for magnesium stearate as it is a pharmaceutical excipient. In research settings, the compound is evaluated for its lubricating properties, flow characteristics, and compatibility with active pharmaceutical ingredients. Its activity is assessed in terms of formulation performance, tablet hardness, and disintegration time rather than direct biological activity.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for magnesium stearate as it is a pharmaceutical excipient. The compound is used in drug formulations to improve manufacturability and is not administered for therapeutic purposes. It is generally considered pharmacologically inert and is not absorbed to a significant extent after oral administration.
|
| Enzyme Assay |
For non-cellular assays, magnesium stearate is characterized by standard analytical techniques including FTIR, X-ray diffraction, and elemental analysis to confirm identity and purity. The compound can be evaluated for its lubricating properties using tablet compression studies. Typical protocols involve mixing the compound with formulation components and measuring tablet hardness, ejection force, and disintegration time. Content of magnesium: 4.00 to 5.00%. Stearic acid composition: min. 60.0%.
|
| Cell Assay |
For in vitro cell-based studies, magnesium stearate is not typically used as a direct test compound. The compound is used as an excipient in pharmaceutical formulations that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken. The compound should be stored in a cool, dry place.
|
| Animal Protocol |
For in vivo animal studies, magnesium stearate is used as an excipient in pharmaceutical formulations administered to animals. The compound is generally considered safe for use in oral formulations. Dosing and administration follow the specific formulation protocol. Standard animal welfare guidelines should be followed for all in vivo studies.
|
| ADME/Pharmacokinetics |
Magnesium stearate has a molecular weight of 591.24 and molecular formula C36H70MgO4. It appears as a fine, light white powder with a slippery feel. Content of magnesium: 4.00 to 5.00%. Stearic acid composition: min. 60.0%. Storage: keep in a cool, dry place. The compound is insoluble in water, ethanol, and ether, but soluble in hot water and hot ethanol.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
The CIR expert panel concluded that, at the current methods of use and concentrations described in the safety assessment, the following ingredient is safe when formulated as non-irritating and non-allergenic, possibly based on a quantitative risk assessment (QRA)... Magnesium stearate is safe for use in cosmetics, but subject to specific conditions. Magnesium stearate is generally regarded as safe for use as a pharmaceutical excipient at appropriate concentrations. The compound is orally non-toxic, but large doses may cause diarrhea or mucosal irritation. Standard laboratory safety practices should be followed when handling this compound. Appropriate personal protective equipment including gloves and safety glasses should be worn. |
| References |
|
| Additional Infomation |
Magnesium distearate is a magnesium salt, and also an organomagnesium salt. See also: stearic acid (containing the active portion).
Magnesium stearate (CAS 557-04-0) is also known as magnesium distearate and stearic acid magnesium(II) salt. It is a widely used pharmaceutical excipient, lubricant, and anti-adherent in capsule and tablet manufacture. The compound is used in the production of medical tablets, capsules, powders, and polymer formulations. No therapeutic claims exist for the compound itself. |
| Molecular Formula |
C36H70MGO4
|
|---|---|
| Molecular Weight |
591.24
|
| Exact Mass |
590.512
|
| CAS # |
557-04-0
|
| PubChem CID |
11177
|
| Appearance |
LUMPS
Fine, bulky, white powder Soft, white, light powder |
| Density |
1.028g/cm3
|
| Boiling Point |
359.4ºC at 760mmHg
|
| Melting Point |
88.5 °C (pure)
; MP: 132 °C /Technical/
; 88 °C
|
| Flash Point |
162.4ºC
|
| Index of Refraction |
1.45 (25ºC)
|
| LogP |
12.508
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
41
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Mg+2].[O-]C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O.[O-]C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
HQKMJHAJHXVSDF-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C18H36O2.Mg/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;/h2*2-17H2,1H3,(H,19,20);/q;;+2/p-2
|
| Chemical Name |
magnesium;octadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6914 mL | 8.4568 mL | 16.9136 mL | |
| 5 mM | 0.3383 mL | 1.6914 mL | 3.3827 mL | |
| 10 mM | 0.1691 mL | 0.8457 mL | 1.6914 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05025917
Conditions:Muscle Weakness|Osteoporosis, PostmenopausalLink: https://clinicaltrials.gov/ct2/show/NCT00702910
Conditions:Pulmonary Disease, Chronic ObstructiveProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
